What's new in the field of prostate cancer chemoprevention?

Current Oncology Reports

Volumn 6, Issue 3, 2004, Pages 237-242

  Mahal, Kanwaljit ^b   Hernandez, Javier ^a   Basler, Joseph W ^b   Thompson, Ian M ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FINASTERIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; SELENIUM;

CANCER DIAGNOSIS; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; MALE; NONHUMAN; PROSTATE CANCER; REVIEW; SEXUAL DYSFUNCTION;

EID: 5444227917     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0055-9     Document Type: Review

References (52)

1. Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2003.
2. Tarone RE, Chu KC, Brawley OW: Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000, 11:167-170.
3. Ries LAG, Eisner MP, Kosary CL, et al., eds: SEER Cancer Statistics Review, 1973-1998. Bethesda, MD: National Cancer Institute; 2002.
4. Potosky AL, Legler J, Albertsen PC, et al.: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000, 92:1582-1592.
5. Clark LT: Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003, 145:387-396.
6. Mehra P: Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002, 17:552-558.
7. Ford LG, Minasian LM, McCaskill-Stevens W, et al.: Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA Cancer J Clin 2003, 53: 2-101.
8. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, et al.: The influence of finasteride of the development of prostate cancer. N Engl J Med 2003, 349:215-224.
9. Imperato-McGinley JL, Guerrero L, Gautier T, et al.: Steroid 5 alpha-reductase deficiency in men: an inherited form of male pseudohermaphroditism. Science 1974, 186:1213.
10. Imperato-McGinley J, Gautier T, Zirinsky K, et al.: Prostate visualization studies in males homozygous and heterozygous for 5-alpha-reductase deficiency. J Clin Endocrinol Metab 1992, 75:1022.
11. Gormley GJ, Stoner E, Rittmaster RS, et al.: Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990, 70:1136-1141.
12. Luo J, Dunn TA, Ewing CM, et al.: Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003, 57:134-139.
13. Tsukamoto S, Akaza H, Onozawa M, et al.: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in raw. Cancer 1998, 82:531-537.
14. Algaba F, Epstein JI, Aldape HC, et al.: Assessment of prostate carcinoma in core needle biopsy: definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996, 78:376-381.
15. Cote RJ, Skinner EC, Salem CE, et al.: The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 1998, 78: 13-418.
16. Thompson IM, Klein EA, Lippman SM: Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003, 44:650-655.
17. Thompson IM, Kouril M, Klein EA, et al.: The Prostate Cancer Prevention Trial: current status and lessons learned. Urology 2001, 57(Suppl 1):230-234.
18. Klein EA, Thompson IM, Lippman SM, et al.: SELECT: The next prostate cancer prevention trial. J Urol 2001, 166: 311-1315.
19. Yoshizawa K, Willett WC, Morris SJ, et al.: Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998, 90:1219-1224.
20. Clark L, Combs G,Turnbull B, et al.: Effects of selenium supplementation for cancer prevention on patients with carcinoma of the skin. JAMA 1996, 276:1957-1963.
21. Duffield-Lillico A, Dalkin BL, Reid ME, et al.: Nutritional Prevention of Cancer Study Group: Selenium supplementation, base-line plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003, 91:608-612.
22. Michiels C, Raes M, Toussaint O: Importance of Se-glutathione peroxidase, catalase, and CU/Zn-SOD for cell survival against oxidative stress. Free Rad Biol Med 1994, 17: 35-248.
23. Gasparian AV, Yao YJ, Lu J, et al.: Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 2002, 1:1079-1087.
24. Jiang C, Wang Z, Ganther H, Lu: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002, 1:1059-1066.
25. Venkateswaran V, Klotz LH, Fleshner NE: Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines Cancer Res 2002, 62: 540-2545.
26. Heinonen OP, Albanes D, Virtano J, et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440-446.
27. Virtamo J, Pietinen P, Huttunen JK, et al.: ATBC Study Group: Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003, 290:476-485.
28. The Heart Outcomes Prevention Study Investigators: Vitamin E supplements and cardiovascular events in high-risk patients. N Engl J Med 2000, 342:154-160.
29. Helzlsouer KJ, Huang HY, Alberg AJ, et al.: Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000, 92: 018-2023.
30. Hayes RB, Bogdanovicz JF, Schroeder FH, et al.: Serum retinol and prostate cancer. Cancer 1988, 62: 021-2026.
31. Leach R, Pollock B, Basler J, et al.: Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials. Urol Clin North Am 2003, 30:227-237.
32. Ni J, Chen M, Zhang Y, et al.: Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003, 300: 57-363.
33. Venkateswaran V, Fleshner NE, Klotz LH: Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002, 168:1578-1582.
34. Zhang Y, Ni J, Messing EM, et al.: Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A 2002, 99:7408-7413.
35. Smith WL, De Witt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-82.
36. Futaki N, Takahashi S, Yokoyama M, et al.: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47:55.
37. Subongkot S, Frame D, Leslie W, Drajer D: Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003, 23:9-28.
38. Koki AT, Leahy KM, Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999, 8:1623-1638.
39. Oshima M, Dinchuk JE, Kargman SL, et al.: Suppression of intestinal polyposis in Apc * 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87: 03-809.
40. Steinbach G, Lynch P, Phillips RKS, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952.
41. O'Neill GP, Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993, 30:156-160.
42. Hsu AL, Ching TT, Wang DS, Song X, et al.: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275:11397-11403.
43. Liu XH, Yau S, Kirschenbaum A, Levine AC: NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998, 58:4245-4249.
44. Liu XH, Kirschenbaum A, Yao S, Lee R, et al.: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000, 164:820-825.
45. Kamijo T, Sato T, Nagatomi Y, Kitamura T: Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol 2001, 8:S35-S39.
46. Gupta S, Srivastava M, Ahmad N, Bostwick DG, et al.: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42:73-78.
47. Roberts RO, Jacobson DJ, Girman CJ, et al.: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002, 77:219.
48. Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000, 7:169-170.
49. Habel LA, Zhao W, Stanford JL: Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002, 13:427-434.
50. Irani J, Ravery V, Pariente JL, et al.: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2002, 168:1985-1988.
51. Pruthi RS, Derksen JE, Gaston K: Re: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2003, 169:2304.
52. Derksen JE, Pruthi RS: COX-2 inhibitors in PSA recurrent prostate cancer: a pilot study [abstract]. J Urol 2002, 167(Suppl):304.